Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529593 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01529593: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01529593 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01529593, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of temsirolimus and metformin hydrochloride in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced or metastatic). Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Metformin hydrochloride is a drug used to treat diabetes that may also prevent or slow the growth of cancers. Giving temsirolimus and metformin hydrochloride together may kill more tumor cells.
Interventions
- DRUG Metformin
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-03-26 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529593
The ClinicalTrials.gov registry entry for NCT01529593 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT01529593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529593 about?
NCT01529593 is a clinical study titled "Temsirolimus in Combination With Metformin in Patients With Advanced Cancers". This phase I trial studies the side effects and best dose of temsirolimus and metformin hydrochloride in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced or metastatic). Temsirolimus may stop the growth of tu...
What is the current status of trial NCT01529593?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-03-26. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT01529593?
The interventions under investigation include: Metformin (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01529593?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.